Simultaneous occurrence of a t(9;22) (Ph) with a t(2;11) in a patient with CML and emergence of a new clone with the t(2;11) alone after imatinib mesylate treatment

Leukemia. 2003 Apr;17(4):807-10. doi: 10.1038/sj.leu.2402877.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Chromosomes, Human, Pair 11 / ultrastructure*
  • Chromosomes, Human, Pair 2 / ultrastructure*
  • Clinical Trials, Phase III as Topic
  • Clone Cells / ultrastructure
  • DNA-Binding Proteins / genetics
  • Disease Progression
  • Enzyme Inhibitors / therapeutic use*
  • Follow-Up Studies
  • Fusion Proteins, bcr-abl / antagonists & inhibitors
  • Histone-Lysine N-Methyltransferase
  • Humans
  • Hydroxyurea / therapeutic use
  • Imatinib Mesylate
  • In Situ Hybridization, Fluorescence
  • Leukemia, Myeloid, Chronic-Phase / drug therapy
  • Leukemia, Myeloid, Chronic-Phase / genetics*
  • Leukemia, Myeloid, Chronic-Phase / pathology
  • Male
  • Middle Aged
  • Myeloid-Lymphoid Leukemia Protein
  • Philadelphia Chromosome*
  • Piperazines / therapeutic use*
  • Proto-Oncogenes*
  • Pyrimidines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Transcription Factors*
  • Translocation, Genetic*

Substances

  • Antineoplastic Agents
  • Benzamides
  • DNA-Binding Proteins
  • Enzyme Inhibitors
  • KMT2A protein, human
  • Piperazines
  • Pyrimidines
  • Transcription Factors
  • Myeloid-Lymphoid Leukemia Protein
  • Imatinib Mesylate
  • Histone-Lysine N-Methyltransferase
  • Fusion Proteins, bcr-abl
  • Hydroxyurea